1. Borroni M et al. Ricerca e Pratica 1997; 4:158-167. 2. American College of Obstetricians and Gynecologists. Guidelines for clinical management of osteoporosis. Obest Gynecol 2004 Jan; 103:203-216. 3. Siris ES et al. JAMA. 2001;286:2815-2822. 4. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773. 5. Marshall D et al. BMJ 1996; 312:1254-1259. 6. Candarette SM et al. JAMA 2001; 286:57-63. 7. Cummings SR et al.JAMA 2000; 283: 1318. 8. Cummings SR et al. Lancet 2002;359: 1761-7. 9. Delmas PD. Lancet 2002;359: 2018-26. 10. Hauselmann HJ, Rizzoli R. Osteoporos Int 2003;14: 2-12. 11. Cranney A et al. Endocr Rev 2002;23: 570-8. 12. Chesnut CH 3rd et al. PROOF Study Group. Am J Med 2000;109: 267-76. 13. Rossouw JE et al. JAMA 2002; 288: 321-333. 14. Dawson-Hughes B et al. N Engl J Med 1997;337: 670-6. 15. Chapuy MC et al. N Engl J Med 1992 ; 327 :1637-1642 16. Neer RM et al. N Engl J Med 2001;344: 1434-41. 17. Van Schoor NM et al. JAMA 2003;289: 1957-62. 18. Bischoff-Ferrari HA et al. JAMA 2004; 291:1999-2006. 19. Bone GH et al. N Engl J Med 2004 ; 350:1189-1199 20. Kern LM et al. Ann Intern Med 2005; 142: 173-181 21. Bodi JJ et al. J Clin Endocrinol Metabol 2002; 87:4528-35 22. Australian Prescriber 2004: 27:22 23. Porthouse J et al. BMJ 2005 Apr 30; 330:1003 24. Grant Am et al. The RECORD Trial Group. Lancet 2005 May 7; 365:1621-1628. 25.Cauley JA et al. Bone Mineral Density and the Risk of Incident Nonspinal Fractures in Black and White Women .JAMA. 2005 May 4; 293:2102-2108 26. Schousboe JT et al. Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women. Ann Intern Med 2005 May 3; 142:734-741 27.Bischoff-Ferrari HA et al.. Fracture Prevention With Vitamin D Supplementation. A Meta-analysis of Randomized Controlled Trials . JAMA. 2005 May 11; 293:2257-2264. 28. FPI’s Clinical Inquiries. Raloxifene for prevention of osteoporotic fractures. Am Fam Physician 2005 Jul 1; 72:132 29. Meunier PJ et al. The effects of strontium ranelateon the risk of the vertebral fractures in women with post-menopausal osteoporosis. N Engl J Med 2004 Jan 29; 350:459-468 30. Reginster JY et al. Strontium ranelate reduce the risk of nonvertebral fracures in post-menopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005, published online Feb 22. 31. Trivedi DP et al. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003 March 1; 326:469-472. 32. Dialogo sui Farmaci 2005; 6:296-297. 33. Jackson RD et al. for the Women's Health Initiative Investigators . Calcium plus Vitamin D Supplementation and the Risk of Fractures. N Engl J Med 2006 Feb 16; 354:669-683 34. Parker MJ et al. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review . BMJ 2006 Mar 11; 332.571-574 35. Prince RL et al. Effects of Calcium Supplementation on Clinical Fracture and Bone Structure. Results of a 5-Year, Double-blind, Placebo-Controlled Trial in Elderly Women. Arch Intern Med. 2006 Apr 24;166:869-875. 36. Drug and Therapeutics Bulletin. Ed. Italiana, vol 44 n.4: 29-32 37. Nayak S et al. Meta-Analysis: Accuracy of Quantitative Ultrasound for Identifying Patients with Osteoporosis. Ann Intern Med 2006 Jun 6; 144: 832-841 38. Vogel VG et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006 Jun 21; 2727-2741. 39. Barrett-Connor E et al. for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women. N Engl J Med 2006 Jul 13; 355:125-127 40. Cranney A et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review . CMAJ 2006 Jul 4; 175:52-59 41. http://www.pillole.org/public/aspnuke/news.asp?id=2744 42. Black DM et al. for the FLEX research Group. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial. JAMA. 2006 Dec 27;296:2927-2938 43. Hillier TA et al. Evaluating the Value of Repeat Bone Mineral Density Measurement and Prediction of Fractures in Older Women. The Study of Osteoporotic Fractures . Arch Intern Med. 2007 Jan 22;167:155-160. 44. Greenspan SL et al. for the Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis. A Randomized Trial . Ann Intern Med 2007 Mar 6; 146:326-339 45. Black DM et al for the HORIZON Pivotal Fracture Trial. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med 2007 May 3; 356:1809-1822 46. Kiel DP et al. Efficacy of a Hip Protector to Prevent Hip Fracture in Nursing Home Residents. The HIP PRO Randomized Controlled Trial . JAMA. 2007 Jul 25;298:413-422. 47. Tang BMP et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007 Aug 25; 370.657-666 48. Robbins J et al. Factors associated with 5-year risk of hip fracture in post.menopausal women. JAMA 2007 Nov 28; 298:2389-2398 49. MacLean C et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis.Ann Intern Med 2008 Feb 5; 148: 197-213. 50. Bischoff-Ferrari HA et al. Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr 2008 Jun; 87:1945-1951 51. Qaseem A et al. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med 2008 Sept 16; 149: 404-415 52. Bischoff-Ferrari HA et al. Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency. A Meta-analysis of Randomized Controlled Trials Arch Intern Med. 2009 Mar 23;169(6):551-561. 53. Smith MR et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009 Aug 20; 361:745. 54. Cummings SR et al. for the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 Aug 20; 361:756.
|
|
